Subscribe Become an Author Sign Up Log In

Jacob Laporte

Contributor Biopharma Insights

Co-Founder & VP, Global Head of BIOME - The Digital Innovation Lab by Novartis.
PhD, Organic Chemistry and Chemical Biology from Harvard University.

   

Pharmaceutical industry trends Thought-provoking

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

The Growth Imperative: Why The Next Big Pharma Competitor Could Be Google Or Apple

   413
The Growth Imperative: Why The Next Big Pharma Competitor Could Be Google Or Apple

In a seminal work published by McKinsey & Company – The Granularity of Growth, a detailed study of the performance of the 100 largest US corporations over the two most recent business cycles – a key finding emerged: top-line growth is vital for survival.

To dig a bit deeper, the study found that a company whose revenue increased slower than the growth of U.S. GDP was five times more likely to falter in the next cycle than a company that expanded more rapidly. Companies have a “Growth Imperative,” which is to either “grow or go,” the authors concluded; in other words, companies must grow faster than their peers or else be left behind.